Sharareh Moraveji, MD
Gastroenterology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 5 carriers
- Office
- 1
Offices
1 location · California Cardiovascular Consultants · 30 clinicians in this group
Hospitals listed: Washington Hospital. That is not proof they admit you there this week.
Plans that list them
15 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Moraveji’s office at (510) 796-0222 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A145642 · Current
Licensed to practise in California · since 2016 · expires 2028-02-29 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$127,138
Medicare paid this office $127,138 for 299 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 128 | $33,300 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 149 | $24,691 | $143 |
| Return visit (30+ min) | 128 | $23,329 | $94 |
| New patient visit (45+ min) | 71 | $8,937 | $126 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $6,311 | $89 |
See all 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 128 | $33,300 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 149 | $24,691 | $143 |
| Return visit (30+ min) | 128 | $23,329 | $94 |
| New patient visit (45+ min) | 71 | $8,937 | $126 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 66 | $6,311 | $89 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 18 | $3,975 | $209 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $3,729 | $162 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $2,972 | $99 |
| Biopsy of large bowel using a flexible endoscope | 22 | $2,270 | $103 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,193 | $183 |
| Insertion of needle into vein for collection of blood sample | 14 | $121 | $9 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 11 | $84 | $8 |
Procedures Medicare counted
| Colonoscopy | 61 | More than 68% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 167 | More than 87% of doctors who do this |
Who their Medicare patients are
299 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 25% · Women 64% · Also on Medicaid 73% · Health risk score 2.30. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 57% · Coronary heart disease 49% · Chronic kidney disease 46% · Heart failure 43% · Atrial fibrillation 38% · COPD 25% · Dementia 24% · Stroke 21% · Depression 19% · Cancer 17%.
The office billed $439,288, Medicare allowed $162,915 and paid $127,138; for 1,311 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 299 | 1,311 | 77 | 2.30 | $439,288 | $127,138 |
| 2023 | 138 | 491 | 76 | 2.15 | $167,524 | $54,991 |
| 2022 | 297 | 1,132 | 76 | 2.27 | $360,163 | $111,364 |
| 2021 | 311 | 1,605 | 76 | 2.33 | $400,195 | $151,172 |
| 2020 | 41 | 95 | 74 | 3.29 | $29,620 | $10,896 |
| 2019 | 14 | 14 | 71 | 2.27 | $2,643 | $1,558 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 64 | $13,518 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $9,806 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,065 | $154 |
| New patient visit (45+ min) | 52 | $7,421 | $143 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 22 | $2,145 | $86 |
| Biopsy of large bowel using a flexible endoscope | 13 | $2,077 | $160 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,415 | $94 |
2022: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 121 | $28,168 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 125 | $22,079 | $160 |
| Return visit (30+ min) | 116 | $19,746 | $101 |
| New patient visit (45+ min) | 67 | $8,598 | $128 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 48 | $4,544 | $93 |
| Diagnostic exam of large bowel using a flexible endoscope | 32 | $4,411 | $138 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $2,942 | $173 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,809 | $97 |
| Biopsy of large bowel using a flexible endoscope | 14 | $2,082 | $149 |
| Breath test analysis for helicobacter pylori | 11 | $734 | $67 |
| Administration of drug for helicobacter pylori | 11 | $86 | $8 |
| Insertion of needle into vein for collection of blood sample | 14 | $45 | $3 |
2021: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 162 | $48,550 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 170 | $34,894 | $177 |
| Return visit (30+ min) | 103 | $21,935 | $115 |
| New patient visit (45+ min) | 59 | $9,042 | $153 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 52 | $5,126 | $93 |
| Diagnostic exam of large bowel using a flexible endoscope | 26 | $4,313 | $166 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $3,238 | $101 |
| Biopsy of large bowel using a flexible endoscope | 17 | $2,715 | $160 |
| Breath test analysis for helicobacter pylori | 20 | $1,482 | $67 |
| Short return visit (20+ min) | 17 | $1,316 | $77 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 29 | $280 | $8 |
| Blood test, comprehensive group of blood chemicals | 24 | $275 | $11 |
| Administration of drug for helicobacter pylori | 20 | $173 | $8 |
| Insertion of needle into vein for collection of blood sample | 35 | $132 | $3 |
2020: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,122 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,565 | $66 |
Medicaid work
$88,189 in 2024
Medicaid paid $88,189 for 1,110 billed services this clinician did in 2024, up to 63 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 396 | $37,179 |
| New patient visit (45+ min) | 203 | $19,448 |
| 1ST HOSP IP/OBS HIGH 75 | 172 | $14,215 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 270 | $11,025 |
| Upper gastrointestinal endoscopy with biopsy | 69 | $6,322 |
| 2024 | 1,110 | 5 | 63 | $88,189 |
| 2023 | 520 | 6 | 45 | $64,640 |
| 2022 | 781 | 5 | 57 | $70,205 |
| 2021 | 866 | 5 | 39 | $73,735 |
| 2020 | 57 | 2 | 20 | $3,962 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 208 | $27,053 |
| New patient visit (45+ min) | 92 | $17,019 |
| Upper gastrointestinal endoscopy with biopsy | 49 | $6,392 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 114 | $6,240 |
| DIAGNOSTIC COLONOSCOPY | 25 | $4,505 |
| 1ST HOSP IP/OBS HIGH 75 | 32 | $3,431 |
2022
| Return visit (30+ min) | 371 | $34,913 |
| New patient visit (45+ min) | 266 | $19,740 |
| DIAGNOSTIC COLONOSCOPY | 62 | $8,115 |
| Upper gastrointestinal endoscopy with biopsy | 55 | $5,147 |
| 1ST HOSP IP/OBS HIGH 75 | 27 | $2,289 |
2021
| Return visit (30+ min) | 319 | $37,447 |
| 1ST HOSP IP/OBS HIGH 75 | 113 | $11,773 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 337 | $11,748 |
| Upper gastrointestinal endoscopy with biopsy | 55 | $6,861 |
| New patient visit (45+ min) | 42 | $5,906 |
2020
| New patient visit (45+ min) | 20 | $2,656 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 37 | $1,306 |
Drugs they prescribed that Part D paid
$22,417
Pharmacies billed $22,417 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 176) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
124 generic and 52 brand-name prescriptions · $22,417 in drug cost · 18 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sutab | 29 | $4,454 | $154 |
| Sucralfate | 12 | $1,556 | $82 |
| Omeprazole | 31 | $563 | $13 |
| Gavilyte-G | 18 | $305 | $16 |
Year by year
| 2024 | 176 | 108 | 0% (0) | 30% | $22,417 |
| 2023 | 105 | 66 | 0% (0) | 16% | $18,874 |
| 2022 | 170 | 98 | 0% (0) | 28% | $11,157 |
| 2021 | 151 | 78 | 0% (0) | 19% | $14,633 |
| 2020 | 19 | 13 | 0% (0) | 0% | $190 |
| 2019 | 36 | 13 | 0% (0) | None | $9,062 |
| 2018 | 53 | 12 | 0% (0) | None | $3,780 |
| 2017 | 58 | 30 | 0% (0) | 26% | $5,242 |
| 2016 | 165 | 33 | None | None | $11,745 |
| 2015 | 253 | 32 | 0% (0) | 27% | $24,225 |
| 2014 | 202 | 34 | None | 30% | $12,034 |
| 2013 | 61 | 20 | None | None | $3,153 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Omeprazole | 31 | $839 | $27 |
| Gavilyte-G | 33 | $603 | $18 |
2022: 3 drugs
| Omeprazole | 38 | $775 | $20 |
| Peg-3350 and Electrolytes | 36 | $435 | $12 |
| Gavilyte-G | 32 | $362 | $11 |
2021: 3 drugs
| Omeprazole | 38 | $765 | $20 |
| Peg-3350 and Electrolytes | 17 | $240 | $14 |
| Peg 3350-Electrolyte | 12 | $194 | $16 |
2018: 1 drug
| Pantoprazole | 20 | $328 | $16 |
2017: 1 drug
| Pantoprazole | 12 | $183 | $15 |
2016: 2 drugs
| Pantoprazole | 11 | $179 | $16 |
| Lisinopril | 25 | $135 | $5 |
2015: 5 drugs
| Pravastatin | 18 | $637 | $35 |
| Carvedilol | 15 | $199 | $13 |
| Lisinopril | 22 | $173 | $8 |
| Amlodipine Besylate | 21 | $169 | $8 |
| Hydrochlorothiazide | 12 | $63 | $5 |
2014: 5 drugs
| Novolin 70-30 | 14 | $2,668 | $191 |
| Pantoprazole | 12 | $313 | $26 |
| Lisinopril | 17 | $152 | $9 |
| Carvedilol | 15 | $136 | $9 |
| Amlodipine Besylate | 13 | $117 | $9 |
Money from drug and device companies
$119 in 2025
| 2025 | 5 | 5 | None | $119 |
| 2024 | 2 | 2 | None | $50 |
| 2023 | 2 | 4 | None | $1,116 |
| 2022 | 6 | 8 | None | $806 |
| 2021 | 3 | 3 | None | $228 |
| 2019 | 6 | 7 | None | $692 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Exact Sciences | Cologuard Collection Kit | $32 | 1 payment
|
| Madrigal Pharmaceuticals | Rezdiffra | $27 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $26 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $20 | 1 payment
|
| Janssen Biotech | Tremfya | $14 | 1 payment
|
See all 5 published payments
| Exact Sciences | Meals · 2025-12-15 | Cologuard Collection Kit | $32 |
| Janssen Biotech | Meals · 2025-06-28 | Tremfya | $14 |
| Sanofi-Aventis U.S. | Meals · 2025-04-15 | Tzield | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-08 | Kerendia | $26 |
| Madrigal Pharmaceuticals | Meals · 2025-02-05 | Rezdiffra | $27 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $50
| Tactile Systems Technology | Flexitouch Plus | $26 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $24 | 1 payment
|
2023: $1,116
| Boston Scientific | Exalt Model D | $1,099 | 3 payments
|
| Braintree Laboratories | Sutab | $18 | 1 payment
|
2022: $806
| Boston Scientific | Exalt Model D | $389 | 3 payments
|
| Abbott Laboratories | Supera | $218 | 1 payment
|
| Abbvie | Mavyret | $96 | 1 payment
|
| Cook Medical | Hemospray | $59 | 1 payment
|
| Lilly USA | Jardiance | $28 | 1 payment
|
| Paratek Pharmaceuticals | Nuzyra | $16 | 1 payment
|
2021: $228
| AbbVie | Mavyret | $119 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $86 | 1 payment
|
| Heron Therapeutics | Zynrelef | $24 | 1 payment
|
2019: $692
| Astellas Pharma US | Xtandi | $125 | 1 payment
|
| Pfizer | Eliquis | $125 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $118 | 2 payments
|
| Amgen | Repatha | $117 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $117 | 1 payment
|
| Shire North American Group | Advate | $90 | 1 payment
|
Professional record
- NPI
- 1144669045
- Licence
- CA A145642California A145642: Current · expires 2028-02-29
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-06-24
- NPI last updated
- 2019-07-03
This is when the NPI record was last certified, not a medical board exam.